Ann: Amplia and Garvan Institute Enter Collaboration Agreement, page-2

Melbourne, Australia: Amplia Therapeutics Ltd (ASX: ATX), (“Amplia” or the “Company”, a company
developing new approaches for the treatment for cancer and fibrosis, is pleased to announce it has
signed a Term Sheet for a Collaboration Agreement with the Garvan Institute of Medical Research
(“Garvan” in Sydney Australia. The Term Sheet defines the structure of a collaborative research and
clinical development program focused on the use of Amplia’s FAK inhibitor, AMP945 to treat patients
with pancreatic cancer.
The collaboration will combine Garvan’s research strength in FAK biology and its extensive clinical
research network with Amplia’s proprietary FAK inhibitors and drug development capability. The
collaboration will initially target new treatment regimens and optimal patient selection strategies for
Amplia’s planned clinical trials of AMP945 in pancreatic cancer patients later this year. Amplia was
awarded an Orphan Drug Designation from the US FDA for this indication in March 2019. The Terms
also provide for expansion of the collaboration into other therapeutic areas.
Amplia’s CEO and Managing Director, Dr John Lambert, commented that “The purpose of this
collaboration is to optimise our planned clinical program for AMP945. Clearly, Garvan’s team has an
unsurpassed understanding of FAK biology and access to an extensive clinical network. By leveraging
Garvan’s deep understanding of the different biological roles that FAK can play, we aim to optimise
the design of our planned clinical trials, recruit the right pancreatic cancer patients and treat them in
the right way, giving AMP945 the best chance for success.”
Professor Paul Timpson, Cancer Research Theme Leader at Garvan, a world-renowned expert in FAK
biology, has been collaborating with Amplia for over a year and will be the lead scientist in the
collaborative research program. Professor Timpson’s group has developed a number of unique
models, assays and tools that provide insights into the biology of both pancreatic cancer cells, and the
fibrotic tumour microenvironment (TME). It is the fibrotic TME that supports the growth of pancreatic
tumours and makes them particularly challenging to treat. The collaborative research program will
evaluate the impact AMP945 can have on these biological processes and use those insights to design
clinical trials for AMP945 in patients with pancreatic cancer. As well as Prof. Timpson’s laboratory, the
collaboration will provide Amplia with access to other scientists and clinicians with expertise in
pancreatic cancer.
Garvan’s Professor Paul Timpson noted that “Our ultimate goal is to translate our cancer research and
FAK biology into better outcomes for patients. We are delighted to work with Amplia so that AMP945
is tested in cancer patients who most need it and also stand to benefit. We are looking forward to
collaborating both before and during Amplia’s planned clinical trials.”
The final Collaboration Agreement is expected to be signed within 90 days. While the terms of the
agreement are confidential, they do include future, success-based payments by Amplia to Garvan on
AMP945 achieving specified clinical, regulatory and commercial sales milestones.
This ASX announcement was approved and authorised for release by the Board of Amplia
Therapeutics.